gallium nitrate
Trade name: ganite
Approved
Jan 17, 1991
Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents. — NCATS
Clinical trial activity
7 trials · 9 clinical orgs · 1 marketing orgs
Earliest trial started Aug 1, 1994 (NCT00002578)
Timeline
1980s
- Dec 5, 1988
Orphan Drug Designation
1990s
- Jan 17, 1991
CheplaPharm — Earliest FDA Approval
- Jan 17, 1991
CheplaPharm — Marketing Organization
- Jan 17, 1991
CheplaPharm — NDA Organization
- Jan 1, 1994
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1995
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
Ribonucleoside-diphosphate reductase RR1 inhibitor
M2 subunit is binding site
- HydroxyapatiteSEQUESTERING AGENT
Hydroxyapatite sequestering agent
enhances crystal formation by binding to hydroxyapatite
Approval history
- approvedPriority reviewJan 17, 1991
Chemistry & pharmacology
SMILES
[Ga+3]- Mol. weight
- 69.723 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaGallium nitrate ↗
- NCATSF7K5MP217W ↗
- ChEMBLCHEMBL1200983 ↗
Also known as
- gallium nitrate
- gallium nitrate
- gallium nitrate
- gallium nitrate
- gallium nitrate
- gallium nitrate
- gallium nitrate
- gallium nitrate
- gallium nitrate
- gallium nitrate, 67ga-labeled
- gallium nitrate (anhydrous)
- gallium nitrate (anhydrous)
- gallium nitrate heptahydrate
- ganite
- ganite
- ganite
- ganite
- ganite
- nitric acid, gallium salt, anhydrate
- nitric acid, gallium salt, anhydrate
- nsc 15200
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04294043 | Phase 1 | May 1, 2020 | Cystic Fibrosis Foundation, University of Washington |
| NCT02354859 | Phase 2 | Mar 1, 2016 | Cystic Fibrosis Foundation Therapeutics, University of Washington |
| NCT01093521 | Phase 1 | Apr 1, 2010 | Cystic Fibrosis Foundation Therapeutics, University of Washington |
| NCT00836173 | Phase 2 | Jul 1, 2008 | Genta, Loyola University |
| NCT00054808 | Phase 2 | Jun 1, 2002 | Genta |
| NCT00002543 | Phase 1 | Feb 1, 1995 | Medical College of Wisconsin, National Cancer Institute (NCI) |
| NCT00002578 | Phase 2 | Aug 1, 1994 | Albany Medical College, National Cancer Institute (NCI), State University of New York, Buffalo |
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Washington | Academic/Hospital | 3 | 3 | 2 | 2010 |
| Cystic Fibrosis Foundation Therapeutics | Academic/Hospital | 2 | 0 | 2 | 2010 |
| Genta | For profit | 2 | 1 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1994 |
| Albany Medical College | Academic/Hospital | 1 | 0 | 1 | 1994 |
| Cystic Fibrosis Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Loyola University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 1995 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 1994 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| CheplaPharm | For profit | MKTG | Jan 17, 1991 |
| CheplaPharm | For profit | NDA | Jan 17, 1991 |